REGISTRATION and NETWORKING

<a href="#hui-cai">Hui Cai</a>, Forum Chair, VP and Head of Content Division, WuXi AppTec

WELCOME

<a href="#ge-li">Ge Li</a>, Chairman, WuXi AppTec and WuXi Biologics

OPENING REMARKS

Are We Breaking New Ground? 
<a href="#david-schenkein">David Schenkein</a>, General Partner, GV 
Antoine Papiernik, Managing Partner, Sofinnova Partners 
<a href="#kristiina-vuori">Kristiina Vuori</a>, President, Sanford Burnham Prebys Medical Discovery Institute 
<a href="#edward-hu">Edward Hu</a>, Co-CEO, WuXi AppTec 
Moderator: <a href="#eric-elenko">Eric Elenko</a>, Chief Innovation Officer, PureTech Health
A Dialogue with Howard “Skip” Burris, President, ASCO; President of Clinical Operations and CMO, Sarah Cannon 
Moderator: <a href="#fred-hausheer">Fred Hausheer</a>, Global Chief Medical Officer and Head of WuXi Oncology, WuXi AppTec

SESSION I: STATE OF INNOVATION

Cell Therapies: Where Are We Heading? 
<a href="#richard-klausner">Richard Klausner</a>, Founder and CEO, Lyell Immunopharma 
<a href="#patrick-hwu">Patrick Hwu</a>, Head, Division of Cancer Medicine, MD Anderson Cancer Center 
Moderator: <a href="#karen-bernstein">Karen Bernstein</a>, Co-Founder and Chairman, BioCentury
Delivering the Promise of Gene Therapies 
<a href="#james-wilson">James Wilson</a>, Professor of Medicine and Pediatrics of Department of Medicine and Director of Gene Therapy Program, University of Pennsylvania 
<a href="#tachi-yamada">Tachi Yamada</a>, Venture Partner, Frazier Healthcare Partners 
Moderator: <a href="#john-carroll">John Carroll</a>, Editor and Founder, Endpoints News

SESSION II: SPOTLIGHT ON CELL AND GENE THERAPIES

A Dialogue with David Liu, Director of the Merkin Institute and Vice-Chair of the Faculty, Broad Institute; Professor of Harvard University and HHMI 
Moderator: Chris Chen, CEO, WuXi Biologics
Incremental or Transformative? 
<a href="#paul-peter-tak">Paul-Peter Tak</a>, President and CEO, Kintai Therapeutics 
<a href="#steve-paul">Steve Paul</a>, Chairman and CEO, Karuna Therapeutics 
<a href="#samantha-du">Samantha Du</a>, Chairman and CEO, Zai Lab 
<a href="#lalo-flores">Lalo Flores</a>, CEO, Century Therapeutics 
Moderator: <a href="#steve-yang">Steve Yang</a>, EVP and CBO, WuXi AppTec

SESSION III: RACE TO THE CURE

A Dialogue with Hans Bishop, CEO, GRAIL 
Moderator: <a href="#melinda-richter">Melinda Richter</a>, Global Head, Johnson &amp; Johnson Innovation, JLABS
How is Technology Shaping the Future of Healthcare? 
<a href="#jason-coloma">Jason Coloma</a>, President and CEO, Maze Therapeutics 
<a href="#zavain-dar">Zavain Dar</a>, Partner, Lux Capital 
<a href="#carolyn-magill">Carolyn Magill</a>, CEO, Aetion 
<a href="#john-halamka">John Halamka</a>, President, Mayo Clinic Platform 
<a href="#leon-wang">Leon Wang</a>, Executive VP International and China President, AstraZeneca 
Moderator: <a href="#kenneth-kaitin">Kenneth Kaitin</a>, Professor and Director, Tufts Center for the Study of Drug Development, Tufts University School of Medicine

SESSION IV: INNOVATION 2030

<a href="#steve-bates">Steve Bates</a>, CEO, UK BioIndustry Association

CLOSING REMARKS

RECEPTION

药明康德JMP-主KV－2020（RGB）

WuXi Global Forum 2020

<a href="#hui-cai">Hui Cai</a>, VP and Head of Content, WuXi AppTec, Program Chair

Welcome

A conversation with <a href="#dietmar-berger">Dietmar Berger</a>, Head of Development and CMO, Sanofi; moderated by <a href="#kevin-da-silva">Kevin Da Silva</a>, Chief Editor, Nature Neuroscience

Session I: Meeting the Challenges in MS and Neuroscience Drug Development

<a href="#tanuja-chitnis">Tanuja Chitnis</a>, Professor of Neurology, Harvard Medical School; Director, Partners Pediatric Multiple Sclerosis Center, Massachusetts General Hospital 
<a href="#mark-freedman">Mark Freedman</a>, Professor of Neurology, University of Ottawa; Sr. Scientist, The Ottawa Hospital Research Institute 
<a href="#ari-green">Ari Green</a>, Chief, Division of Neuroinflammation and Glial Biology, Medical Director, Multiple Sclerosis and Neuroinflammation Center, UCSF 
<a href="#cyndi-zagieboylo">Cyndi Zagieboylo</a>, President and CEO, National MS Society 
Moderated by <a href="#mandy-jackson">Mandy Jackson</a>, Managing Editor of US Commercial News for Scrip and The Pink Sheet

Session II: Clinical Prospects for a Challenging Disease

<a href="#joachim-herz">Joachim Herz</a>, Professor, Molecular Genetics, Neuroscience, Neurology; Director, Center for Translational Neurodegeneration Research, UT Southwestern Medical Center 
<a href="#ralph-kern">Ralph Kern</a>, President and Chief Medical Officer, Brainstorm Cell Therapeutics 
<a href="#dan-lorrain">Dan Lorrain</a>, Chief Scientific Officer, Pipeline Therapeutics 
<a href="#krish-ramanathan">Krish Ramanathan</a>, Global Program Head, Neuroscience and Global Drug Development, Novartis 
Moderated by <a href="#richard-soll">Richard Soll</a>, Head of WuXi AppTec’s Boston office; Senior Advisor of Strategic Initiatives

Session III: New Directions in MS Therapies

As an industry enabler, WuXi AppTec is committed to improving the lives of patients globally. We share the conviction that we must work collaboratively to solve industry-wide challenges and bring transformative medicines to patients.
We welcome you to the conversation.

Closing

WXpress1485X973

Emerging Opportunities in Multiple Sclerosis and Neurosciences

<a href="#hui-cai">Hui Cai</a>, VP and Head of Content, WuXi AppTec, Program Chair

A conversation with <a href="#paulo-fontoura">Paulo Fontoura</a>, Global Head and SVP, Neuroscience and Rare Diseases Clinical Development, Roche; moderated by <a href="#david-chang">David Chang</a>, CEO, WuXi Advanced Therapies, WuXi AppTec

Session I: Perspective on Global Development and Access to Medicines in Rare Diseases

<a href="#kristin-schneeman">Kristin Schneeman</a>, Director, FasterCures, a center of the Milken Institute 
<a href="#mencia-de-lemus">Mencía de Lemus</a>, President of SMA Europe; President of FundAME, National SMA patient organisation, Spain 
<a href="#laurent-servais">Laurent Servais</a>, Professor of Paediatric Neuromuscular Diseases, Neuromuscular Reference Center Disease, Department of Paediatrics, Liège, Belgium; MDUK Neuromuscular Center, Department of Paediatrics, University of Oxford, UK 
Moderated by <a href="#lauren-martz">Lauren Martz</a>, Senior Editor, Head of Translation &amp; Clinical Development, BioCentury

Session II: Patients at the Center

<a href="#karen-chen">Karen Chen</a>, CEO, Spinal Muscular Atrophy Foundation 
<a href="#stanley-crooke">Stanley Crooke</a>, Chairman of the Board and CEO, Ionis Pharmaceuticals; Founder, CEO and Chairman of the Board, n-Lorem Foundation 
<a href="#thomas-crawford">Thomas Crawford</a>, Professor of Neurology and Pediatrics, Johns Hopkins Hospital, Johns Hopkins Children’s Center, Kennedy Krieger Institute 
<a href="#oscar-henry-mayer">Oscar Henry Mayer</a>, Professor of Clinical Pediatrics, The Perelman School of Medicine at the University of Pennsylvania, Division of Pulmonology, Children’s Hospital of Philadelphia 
Moderated by <a href="#richard-soll">Richard Soll</a>, Head of WuXi AppTec’s Boston office; Senior Advisor of Strategic Initiatives

Session III: Translating Fundamentals into Meaningful Therapeutics

WXpress1485X973_tall

Rare Disease: Spinal Muscular Atrophy

REGISTRATION AND NETWORKING

<div>
<div>Host: <a href="#hui-rai">Hui Cai</a>, Forum Chair; Vice President of PR &amp; Communications, WuXi AppTec</div>
<div></div>
</div>
<div></div>

<div>
<div><a href="#ge-li">Ge Li</a>, Chairman, WuXi AppTec and WuXi Biologics</div>
</div>

Innovation is at the core of the healthcare system. In this panel, some of our industry’s top leaders bring together diverse and fresh perspectives on new ways to enhance connectivity, productivity, and efficiency in delivering better medicines for patients. 
Moderator: <a href="#edward-hu">Edward Hu</a>, Co-CEO, WuXi AppTec 
<a href="#mathai-mammen">Mathai Mammen</a>, Global Head, Research &amp; Development 
The Janssen Pharmaceutical Companies of Johnson &amp; Johnson 
<a href="#tom-lynch">Tom Lynch</a>, EVP and CSO, BMS 
<a href="#laurie-glimcher">Laurie Glimcher</a>, President and CEO, Dana-Faber Cancer Institute 
<a href="#moncef-slaoui">Moncef Slaoui</a>, Partner, Medicxi Life Sciences VC

REWIRING R&D

From tough targets to disruptive technologies to new modalities, this panel of startup CEOs and investors explain their bold moves, and what will shape 2019 and beyond. 
Moderator: <a href="#michael-gilman">Michael Gilman</a>, Chairman and CEO, Arrakis Therapeutics 
<a href="#bob-hariri">Bob Hariri</a>, Founder, Chairman and CEO, Celularity 
<a href="#sander-slootweg">Sander Slootweg</a>, Managing Partner, Forbion 
<a href="#john-evans">John Evans</a>, CEO, Beam Therapeutics; Venture Partner, ARCH Venture Partners 
<a href="#andy-schwab">Andy Schwab</a>, Managing Partner, 5AM Ventures

LAUNCHPAD 2018

Healthcare is ripe for transformation. What is the magic touch that effects change? We ask two visionaries on the 2018 Forbes Midas List of the world’s top venture capital investors to share their thoughts. 
Moderator: <a href="#steve-yang">Steve Yang</a>, EVP and CBO, WuXi AppTec 
<a href="#neil-shen">Neil Shen</a>, Global Steward, Sequoia Capital; Founding and Managing Partner, Sequoia China 
<a href="#robert-nelsen">Robert Nelsen</a>, Managing Director and Co-Founder, ARCH Venture Partners

THE MIDAS TOUCH

How would the future of R&amp;D and healthcare look like in a world involving real-world evidence and decision making informed by genomics, big data, and artificial intelligence? 
Moderator: <a href="#robert-urban">Robert Urban</a>, Retired Global Head of Johnson &amp; Johnson Innovation 
<a href="#blake-byers">Blake Byers</a>, General Partner, Google Ventures 
<a href="#daphne-koller">Daphne Koller</a>, CEO and Founder, insitro 
<a href="#rob-brainin">Rob Brainin</a>, CEO, WuXi NextCODE 
<a href="#ken-mulvany">Ken Mulvany</a>, Founder and Chairman, BenevolentAI 
<a href="#deb-kilpatrick">Deb Kilpatrick</a>, CEO, Evidation Health

“FUTURE PROOFING” HEALTHCARE

<div>
<div><a href="#joseph-panetta">Joseph Panetta</a>, Cohost; President and CEO, Biocom</div>
</div>

WuXi Forum 2019 Web banner_1680x812px

WuXi Global Forum 2019

A conversation with <a href="#glenn-pierce">Glenn Pierce</a>, VP Medical, World Federation of Hemophilia, Entrepreneur-in-Residence at Third Rock Ventures, and Chief Medical Officer at Ambys Medicines; moderated by <a href="#hui-cai">Hui Cai</a>, VP and Head of Content Division, WuXi AppTec

Addressing the Unknowns in an Era of Transformations

<a href="#federico-mingozzi">Federico Mingozzi</a>, Chief Scientific Officer, Spark Therapeutics 
<a href="#john-pasi">John Pasi</a>, Professor of Haemostasis and Thrombosis, Barts and the London School of Medicine and Dentistry, Queen Mary University of London 
<a href="#richard-pezzillo">Richard Pezzillo</a>, Executive Director, New England Hemophilia Association 
<a href="#glenn-pierce">Glenn Pierce</a>, VP Medical, World Federation of Hemophilia 
<a href="#rogerio-vivaldi">Rogerio Vivaldi</a>, President &amp; Chief Executive Officer, Sigilon Therapeutics 
<a href="#guy-young">Guy Young</a>, Director, Hemostasis and Thrombosis, Children’s Hospital Los Angeles; Professor of Pediatrics, University of Southern California Keck School of Medicine 
Moderated by <a href="#richard-soll">Richard Soll</a>, Head of WuXi AppTec’s Boston office; Senior Advisor of Strategic Initiatives

The Quest for Transformative Medicines

WXpress首页

Advances in Rare Diseases: Hemophilia

<a href="#hui-cai">Hui Cai</a>, VP and Head of Content, WuXi AppTec

This session highlights the important roles patients and healthcare professionals play in biomedical advances, and together with researchers, drug developers, and advocacy groups, collaborate to benefit neurofibromatosis and rare disease patients worldwide.
<a href="#bruce-korf">Bruce Korf</a>, Associate Dean for Genomic Medicine, UAB School of Medicine; Chief Genomics Officer, UAB Medicine 
<a href="#renie-moss">Renie Moss</a>, NF1 patient advocate and family member 
<a href="#jaishri-blakeley">Jaishri Blakeley</a>, The Marjorie Bloomberg Tiven Professor of Neurofibromatosis, Johns Hopkins University School of Medicine; Director, the Neurofibromatosis Therapeutic Acceleration Program 
<a href="#mcKinnon-galloway">McKinnon Galloway</a>, NF2 patient 
<a href="#gareth-evans">Gareth Evans</a>, Professor of Medical Genetics and Cancer Epidemiology, The University of Manchester 
<a href="#dale-berg">Dale Berg</a>, Schwannomatosis patient 
Hosted by <a href="#luke-timmerman">Luke Timmerman</a>, Founder and Editor, Timmerman Report

Track One: Perspectives from Clinicians and Patients

KOSELUGO® (selumetinib), a MEK inhibitor from AstraZeneca and MSD (Merck in the US), was approved by the U.S. FDA in April 2020 as the first NF1 drug to treat children with plexiform neurofibromas, while Brigatinib is under clinical evaluation for the treatment of NF2 through a mechanism that is distinct from ALK activity. In both cases, these drugs were discovered through collaborative, non-traditional conduits.
<a href="#scott-plotkin">Scott Plotkin</a>, Neuro-Oncologist; Executive Director, Pappas Center for Neuro-Oncology, Massachusetts General Hospital; Professor of Neurology, Harvard Medical School 
<a href="#annette-bakker">Annette Bakker</a>, President, Children’s Tumor Foundation 
<a href="#george-kirk">George Kirk</a>, Koselugo Global Product Leader, AstraZeneca 
<a href="#brigitte-widemann">Brigitte Widemann</a>, Chief, Pediatric Oncology Branch, NCI, NIH; Head, Pharmacology and Experimental Therapeutics Section 
<a href="#mike-humphries">Mike Humphries</a>, US Medical Affairs Scientific Director for Lung Cancer, Takeda Oncology 
Moderated by <a href="#richard-soll">Richard Soll</a>, Head of Boston Office and Senior Advisor of Strategic Initiatives, WuXi AppTec

Track Two: Non-Traditional Research & Development: The Making of the Breakthrough Therapy KOSELUGO® (Selumetinib) for NF1 and the Promise of Brigatinib to Treat NF2

As an enabler in the biotech and medical device industry, WuXi AppTec shares our common conviction that we must work collaboratively to solve industry-wide problems and bring transformational medicines to patients.

nf webinar

Rare Disease Neurofibromatosis

<a href="#hui-cai">Hui Cai</a>, Vice President and Head of Content, WuXi AppTec

Remembering the Lives Lost to COVID-19 

<a href="#jim-greenwood">Jim Greenwood</a>, CEO, Biotechnology Innovation Organization (BIO) 
Moderated by <a href="#edward-hu">Edward Hu</a>, Co-CEO, WuXi AppTec

COVID-19: A Defining Moment

<a href="#william-morice">William Morice</a>, President, Mayo Clinic Laboratories 
Moderated by <a href="#carolyn-magill">Carolyn Magill</a>, CEO, Aetion

Diagnosis: Lessons from the Battlefield

<a href="#johan-van-hoof">Johan Van Hoof</a>, Global Therapeutic Area Head IDV, Vaccines, Janssen Pharmaceuticals R&amp;D and Managing Director, Janssen Vaccines &amp; Prevention, B.V. 
<a href="#phil-pang">Phil Pang</a>, Chief Medical Officer, Vir Biotechnology 
<a href="#john-maraganore">John Maraganore</a>, CEO, Alnylam Pharmaceuticals 
<a href="#chad-robins">Chad Robins</a>, CEO &amp; Co-Founder, Adaptive Biotechnologies 
Moderated by <a href="#steve-yang">Steve Yang</a>, EVP and CBO, WuXi AppTec

Development in Time of Crisis

<a href="#arnaud-bernaert">Arnaud Bernaert</a>, Head of Shaping the Future of Health and Healthcare, World Economic Forum 
Moderated by <a href="#steve-usdin">Steve Usdin</a>, Senior Editor and Head of Policy, BioCentury

The Future of Epidemic Readiness

covid19-forum-2-image

Harnessing Our Collective Power: WuXi Online Forum II on COVID-19

<a href="#hui-cai">Hui Cai</a>, Forum Chair, Vice President and Head of Content Division, WuXi AppTec

OPENING

A Moment of Silence for the Lives Lost to COVID-19

<a href="#feng-zhang">Feng Zhang</a>, Investigator, Howard Hughes Medical Institute; Core Member, Broad Institute of MIT and Harvard 
<a href="#charles-chiu">Charles Chiu</a>, Professor, Laboratory Medicine and Medicine / Infectious Diseases; 
Director, UCSF-Abbott Viral Diagnostics and Discovery Center 
<a href="#victor-shi">Victor Shi</a>, CEO, Adicon Clinical Laboratories; General Partner, Serica Partners 
Moderated by <a href="#nick-naclerio">Nick Naclerio</a>, Founding Partner, Illumina Ventures

Towards Faster and More Accurate Diagnosis

<a href="#george-scangos">George Scangos</a>, CEO, Vir Biotechnology 
<a href="#tomas-cihlar">Tomas Cihlar</a>, Vice President of Virology, Gilead Sciences 
<a href="#david-ho">David Ho</a>, Director of Aaron Diamond AIDS Research Center; Professor of Medicine, Columbia University Vagelos College of Physicians and Surgeons 
<a href="#chris-chen">Chris Chen</a>, CEO of WuXi Biologics; Chairman, WuXi Vaccines 
Moderated by <a href="#zhi-hong">Zhi Hong</a>, Co-founder and CEO, Brii Biosciences

Expediting Therapeutic Intervention

<a href="#gregory-poland">Gregory Poland</a>, Professor and Director of Mayo Clinic Vaccine Research Group; Editor-in-Chief, VACCINE 
<a href="#johan-van-hoof">Johan Van Hoof</a>, Global Therapeutic Area Head IDV, Vaccines, Janssen Pharmaceuticals R&amp;D and Managing Director, Janssen Vaccines &amp; Prevention, B.V. 
<a href="#joseph-kim">Joseph Kim</a>, President and CEO, Inovio Pharmaceuticals 
<a href="#xuefeng-yu">Xuefeng Yu</a>, Chairman and CEO, CanSino Biologics 
<a href="#mark-esser">Mark Esser</a>, Vice President of Microbial Sciences, AstraZeneca 
Moderated by <a href="#steve-yang">Steve Yang</a>, EVP and CBO, WuXi AppTec

Can We Move Quickly on Vaccines?

<a href="#arthur-reingold">Arthur Reingold</a>, Division Head of Epidemiology and Biostatistics, UC Berkeley School of Public Health 
Moderated by <a href="#rich-soll">Rich Soll</a>, Senior Advisor of Strategic Initiatives and Head of Boston Office, WuXi AppTec

Events

EVENT RECAP

WuXi Global Forum 2020

WuXi Global Forum

EVENT RECAP

Emerging Opportunities in Multiple Sclerosis and Neurosciences

Events

EVENT RECAP

Rare Disease: Spinal Muscular Atrophy

Events

EVENT RECAP

Advances in Rare Diseases: Hemophilia

Events

EVENT RECAP

Rare Disease Neurofibromatosis

Events

EVENT RECAP

Harnessing Our Collective Power: WuXi Online Forum II on COVID-19

Events

EVENT RECAP

LET SCIENCE LEAD: A Special Online Forum on COVID-19

Events

EVENT RECAP

WuXi Global Forum 2019

WuXi Global Forum

Featured

Rare Disease: Spinal Muscular Atrophy

Events

WuXi Global Forum 2019

WuXi Global Forum